2-Fluoroethamphetamine
2-Fluoroethamphetamine (2-FEA) is the N-ethyl homologue of 2-fluoroamphetamine, sold briefly as a research-chemical stimulant. It is essentially uncharacterised in humans and is described anecdotally as a milder, longer stimulant.
01 Overview
2-FEA combines ring fluorination at the 2-position with an N-ethyl group. N-ethylation generally reduces potency relative to the corresponding N-methyl or primary amine while lengthening duration, and this pattern is reflected in the sparse user reports.
No pharmacokinetic, toxicological or clinical data exist. The compound appeared alongside other fluorinated amphetamines and disappeared quickly; everything documented here is anecdotal or inferred from close structural relatives.
02 Mechanism
Presumed substrate-type releaser of dopamine and noradrenaline, analogous to other N-alkylated fluoroamphetamines.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Common | 15–35 mg | Insufflated | Unstudied; harsh nasally. |
| Common | 20–50 mg | Oral | Anecdotal only; no validated dosing. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Mild stimulationReported gentle, functional energy increase. | Anecdotal | ||
| Increased sociabilitySome users report mild talkativeness. | Anecdotal | ||
| Appetite suppressionReduced hunger typical of the class. | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| InsomniaSleep disruption after dosing. | Moderate | Common | Anecdotal | |
| AnxietyRestlessness and anxiety, dose-dependent. | Moderate | Common | Anecdotal | |
| Cardiovascular strainElevated heart rate and blood pressure expected from the class. | Severe | Common | Unconfirmed |